Company Description
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings.
The company was incorporated in 2013 and is based in Salt Lake City, Utah.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jul 12, 2017 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 132 |
| CEO | Dwight Egan |
Contact Details
Address: 2401 S. Foothill Dr., Suite D Salt Lake City, Utah 84109 United States | |
| Phone | (801) 438-1036 |
| Website | co-dx.com |
Stock Details
| Ticker Symbol | CODX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001692415 |
| CUSIP Number | 189763105 |
| ISIN Number | US1897631057 |
| Employer ID | 46-2609396 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dwight H. Egan | Chairman and Chief Executive Officer |
| Richard David Abbott | President |
| Brian L. Brown CPA | Chief Financial Officer and Company Secretary |
| David Nielsen | Chief Operating Officer |
| Dan Bohrer CPA | Vice President of Finance and Accounting |
| Christopher Thurston | Chief Technology Officer |
| Andrew Benson | Head of Investor Relations |
| Dr. Mayuranki Almaula Ph.D. | Senior Vice President of Overseas Operations and Strategic Alliances |
| Seth Egan | Chief Commercialization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | 8-K | Current Report |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 21, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Nov 8, 2024 | 8-K/A | [Amend] Current report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 18, 2024 | 424B5 | Filing |